Cargando…

Dabigatran must be used carefully: literature review and recommendations for management of adverse events

Atrial fibrillation increases the risk of stroke and death. The vitamin-K antagonist warfarin is recommended for patients with atrial fibrillation, but vitamin-K antagonists are cumbersome to use. Therefore, an effective, safe and convenient new anticoagulant is needed. Dabigatran acts by inhibiting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Shan, Wang, Yan, Zhang, Lei, Guan, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6511609/ https://www.ncbi.nlm.nih.gov/pubmed/31190734 http://dx.doi.org/10.2147/DDDT.S203112

Ejemplares similares

Adverse events in patients initiated on dabigatran etexilate therapy in a pharmacist-managed anticoagulation clinic
por: Donaldson, Mark, et al.
Publicado: (2013)

Cardioversion and Risk of Adverse Events with Dabigatran versus Warfarin—A Nationwide Cohort Study
por: Pallisgaard, Jannik Langtved, et al.
Publicado: (2015)

Dabigatran Excess: Case Report and Review of the Literature
por: Sarma, Amy, et al.
Publicado: (2013)

Fatal Adverse Events of Dabigatran Combined With Aspirin in Elderly Patients: An Analysis Using Data From VigiBase
por: Zhang, Qingxia, et al.
Publicado: (2021)

Evaluation of Dabigatran- and Warfarin-Associated Hemorrhagic Events Using the FDA-Adverse Event Reporting System Database Stratified by Age
por: ABE, Junko, et al.
Publicado: (2015)

Dabigatran in cardiovascular disease management: A comprehensive review
por: Javed, Ayesha, et al.
Publicado: (2021)

Venovenous haemodiafiltration for the management of dabigatran overdose in intensive care unit
por: Claisse, Guillaume, et al.
Publicado: (2015)

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management
por: Apalla, Zoe, et al.
Publicado: (2021)

Management of Major Bleeding Events in Patients Treated With Dabigatran for Nonvalvular Atrial Fibrillation: A Retrospective, Multicenter Review
por: Milling, Truman J., et al.
Publicado: (2017)

Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)

The Dabigatran debate
por: Kaba, Riyaz A, et al.
Publicado: (2014)

Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel()()
por: Cury-Martins, Jade, et al.
Publicado: (2020)

Dabigatran: patient management in specific clinical settings
por: Kyrle, Paul Alexander, et al.
Publicado: (2014)

Management of dabigatran-induced bleeding: expert statement
por: Fries, Dietmar, et al.
Publicado: (2013)

Intravenous Thrombolysis After Dabigatran Reversal by Idarucizumab: A Systematic Review of the Literature
por: Frol, Senta, et al.
Publicado: (2021)

FDA committee unanimously recommends approval of dabigatran etexilate for stroke prevention in atrial fibrillation
por: J, Aalbers, et al.
Publicado: (2010)

How high must lactate be to predict an adverse outcome?
por: Blaser, A Reintam, et al.
Publicado: (2011)

Dabigatran etexilate tetrahydrate
por: Liu, Hong-Qiang, et al.
Publicado: (2012)

Dabigatran-Induced Massive Spontaneous Hemothorax
por: Huang, Jing, et al.
Publicado: (2017)

Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012)

Adverse Events Associated with Fosfomycin Use: Review of the Literature and Analyses of the FDA Adverse Event Reporting System Database
por: Iarikov, Dmitri, et al.
Publicado: (2015)

Prioritising recommendations following analyses of adverse events in healthcare: a systematic review
por: Bos, Kelly, et al.
Publicado: (2020)

The Discovery of Dabigatran Etexilate
por: van Ryn, Joanne, et al.
Publicado: (2013)

Dabigatran and apolipoprotein B
por: ten Cate, Hugo
Publicado: (2016)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Consensus Recommendations for Management and Counseling of Adverse Events Associated With Lorlatinib: A Guide for Healthcare Practitioners
por: Reed, Mollie, et al.
Publicado: (2020)

Clinical recommendations for perioperative immunotherapy‐induced adverse events in patients with non‐small cell lung cancer
por: Ni, Jun, et al.
Publicado: (2021)

Correction to: Dabigatran-Induced Massive Spontaneous Hemothorax
por: Huang, Jing, et al.
Publicado: (2017)

Safety of idarucizumab in the reversal of dabigatran at six tertiary care Ontario hospitals
por: Abdulrehman, Jameel, et al.
Publicado: (2021)

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
por: Glund, Stephan, et al.
Publicado: (2018)

The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran
por: Alikhan, Raza, et al.
Publicado: (2014)

Choice of Renal Function Estimator Influences Adverse Outcomes with Dabigatran Etexilate in Patients with Atrial Fibrillation
por: Simpson, Bryan H., et al.
Publicado: (2018)

Dabigatran-induced esophagitis: A case report
por: Zhou, Yi, et al.
Publicado: (2020)

Specific Point-of-Care Testing of Coagulation in Patients Treated with Dabigatran
por: Härtig, Florian, et al.
Publicado: (2021)

Cost of dabigatran for atrial fibrillation
por: Gage, Brian F
Publicado: (2011)

Pharmacometric Characterization of Dabigatran Hemodialysis
por: Liesenfeld, Karl-Heinz, et al.
Publicado: (2013)

Dabigatran for left atrial thrombus
por: Morita, Sae, et al.
Publicado: (2013)

Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012)

Dabigatran Associated Leukocytoclastic Vasculitis
por: Potolidis, Evangelos, et al.
Publicado: (2015)

Interstitial pneumonia caused by dabigatran
por: Yanagihara, Toyoshi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ao16d0qa7k7ivlg44lg0alqi5l